Our latest news release for trade media highlights our pre-clinical siRNA delivery systems Nuvec® and LipTide®.
LipTide® is a lipid and peptide-based delivery system developed by Nanogenics and is currently being used in the formulation of a novel siRNA product, ECP105, which is targeting an unmet clinical need in the ophthalmology market for glaucoma patients.
N4 Pharma continues to show positive results in its pre-clinical research programme into Nuvec®, especially in the key areas of siRNA and oral delivery.
Read the full release here.
We were pleased to share our latest updates with the pharmaceutical and biopharmaceutical trade press and some key publications in this field have published it:
- Ophthalmology Times: https://bit.ly/3UZcmeS
- Ophthalmology Breaking News: https://bit.ly/3UY2K4e
- Technology Networks: https://bit.ly/3wwsPNn
- Manufacturing Chemist: https://bit.ly/3Tm39fB
- Biospace: https://bit.ly/3T6K3IR
